Q2-2019 Outsourced Pharma Services Update– The CDMO sector has continued to consolidate at a rapid pace, particularly in North America. Specialist providers in biologics and gene therapy are receiving competitive valuations, while API and FDF competence continues to motivate acquirers.
Consolidation in Outsourced Pharmaceutical Services– Contract Research Organizations (CROs) and Contract Development & Manufacturing Organizations (CDMOs) are utilizing strategic mergers, acquisitions, and private equity partnerships to capitalize on tailwinds in the outsourced pharmaceutical services sector.
The Health-Care M&A Meter: Hot 2018 to Be Followed by Hotter 2019– The outlook for health-care mergers and acquisitions in 2019 suggests even more transactions this year as compared to 2018, with activity in the hospital and health system sector expected to continue, as well as increasing volume of deals in the physician services, home health. and health-care IT sectors.
Q4-2018 CRO Update – The Contract Research market continues to demonstrate substantial growth, in large part due to increasing demand for services in clinical trials between Phases II and IV, which account for the majority of the industry’s revenue. Private equity was the driving force behind much of the consolidation in 2018 and the fourth quarter was no different with two of the three transactions involving a private equity or PE-backed acquirer.